|Biotech Due Diligence||
Editor's note: I am thrilled once again to present a guest post from Dr. Duncan Emerton, author of the Biosimilarz blog. Enjoy Duncan's wrap up of the busy year 2014 and his look ahead at what is in store for 2015.
Don't miss the Biosimilarz Twitter feed and podcast series as well.
You can also revisit Duncan's "2013 Biosimilars in Review"
BiotechDueDiligence is pleased to continue an occasional collaboration with The Biosimilarz Blog by hosting the latest edition of Dr. Duncan Emerton's podcast highlighting recent developments in the world of biosimilars. Click here to access the podcast audio for this and prior editions of the podcast.
Featured companies: $AMGN, Epirus Biopharma, Celltrion, $PFE, $NVS Sandoz, $HSP, Dr. Reddy's
Nature Outlook: Epilepsy [collection of free articles]
Clinical Trial Transparency — Antidote to Weaker Off-Label-Promotion Rules?
Keith Outterson. New England Journal of Medicine.
U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009.
Morgan-Linnell et al. Clinical Cancer Research.
Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks
Stephen Strittmatter. Nature Medicine.
Drug Companies' Patient-Assistance Programs — Helping Patients or Profits?
David Howard. New England Journal of Medicine.
FDA sets hierarchy for biosimilars evidence
Mark Ratner. Nature Biotechnology.